Objective: Repeat adolescent pregnancy is a hot topic worldwide and imposes a challenge on the health system, especially when faced with limited resources. We aimed to assess maternal and neonatal outcomes in adolescent pregnant women with one prior cesarean section (CS).
Material And Methods: Singleton adolescent pregnant women with one prior CS scar were recruited and divided into two groups based on the obstetric decision for delivery and/or mother’s wish, either trial of labor (TL) or elective cesarean section (ECS). If TL failed, an emergency CS was performed.
Results: Out of the total 109 involved women, TL and ECS groups included 78 (71.6%) and 31 (28.4%) women, respectively. Emergency CS was done for 57 (52.3%) women from the TL group, leaving only 21 (19.3%) women with successful TL who had statistically significant (non-recurrent) indications of the prior CS [12 (57.1%)]. Malpresentation (n=24; 77.4%) was the major indication in the ECS group, while fetal distress (n=29; 50.9%) was the main cause of failed TL. Total maternal morbidities in the TL group were significantly higher for adjusted [1.5 (1.1-4.2)] and non-adjusted odds ratios (OR) [2.4 (1.6-5.6)]. Neonatal complications, such as admission to neonatal intensive care unit, were higher in the TL group without reaching significance. However, the adjusted OR [1.9 (1.1-3.3)] for perinatal asphyxia was significantly increased in TL group.
Conclusion: Maternal morbidities and perinatal asphyxia were significantly higher in the TL group of adolescent women compared with the ECS group in this study.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258566 | PMC |
| http://dx.doi.org/10.4274/jtgga.galenos.2023.2022-7-11 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mental Disorders Among Offspring Prenatally Exposed to Systemic Glucocorticoids.
JAMA Netw Open
January 2025
Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus University, Aarhus, Denmark.
Importance: Current evidence of the association between prenatal exposure to glucocorticoids and long-term mental disorders is scarce and has limitations.
Objective: To investigate the association between prenatal exposure to systemic glucocorticoids and mental disorders in offspring at the age of 15 years, comparing exposed vs unexposed offspring born to mothers with the same underlying disease (risk of preterm delivery and autoimmune or inflammatory disorders).
Design, Setting, And Participants: This nationwide population-based cohort study used data from registries in Denmark with follow-up until December 31, 2018.
Safety of antenatal breastmilk expression from week 34 of pregnancy: a randomized controlled pilot study (The Express-MOM study).
Matern Health Neonatol Perinatol
January 2025
Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.
Background: Mother's own milk (MOM) is important as the first nutrition for preterm infants, but mothers often struggle to initiate milk production right after preterm birth. If antenatal breastmilk expression (aBME) does not induce preterm labor when performed before term age, it could promote nutrition with MOM right after preterm birth. In this pilot study, we aimed to investigate whether aBME induces preterm labor among healthy nulliparous women from week 34 of pregnancy, to examine if aBME promotes the availability of MOM right after birth and affects breastfeeding outcomes.
View Article and Find Full Text PDFEvaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084.
J Int AIDS Soc
January 2025
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Introduction: Long-acting injectable cabotegravir (CAB-LA) for pre-exposure prophylaxis significantly reduced HIV acquisition in HPTN 084. We report on the safety and CAB-LA pharmacokinetics in pregnant women during the blinded period of HPTN 084.
Methods: Participants were randomized 1:1 to either active cabotegravir (CAB) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) placebo or active TDF/FTC plus CAB placebo.
CROI 2024: The Challenges of Sustained Viral Suppression, Advanced HIV Disease, and Ending the HIV Epidemic Targets.
Top Antivir Med
August 2024
New York Blood Center, New York, New York, USA.
Data on the HIV care cascade demonstrated challenges in achieving Ending the HIV Epidemic (EHE) targets across all 18 EHE focus metropolitan areas, but innovative adherence interventions using point-of-care tenofovir testing and motivational interviewing support care cascade outcomes in Namibia and South Africa, respectively. Data on treatment with long-acting injectable (LAI) antiretroviral therapy (ART) demonstrated high acceptability, retention, and virologic suppression including in groups that were not well represented in clinical trials including persons born female and persons with detectable viral loads. The adjuvanted hepatitis B vaccine appeared to be safe and appeared to be superior to conventional hepatitis B vaccines in persons with HIV (PWH) who were prior nonresponders to the hepatitis B vaccine.
View Article and Find Full Text PDFEfficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial.
Obstet Gynecol
January 2025
Children's Hospital Colorado, Aurora, Colorado; Vaccine Research and Development, Pfizer Inc, Pearl River, New York; the South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit and Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, and Famcru, Department of Paediatrics and Child Health, University of Stellenbosch, and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, SA-MRC Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa; Vaccines and Immunity Team, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, the Gambia; Institute for International Health Charité, Universitätsmedizin, Berlin, Germany; Vaccine Research and Development, Pfizer Ltd, Marlow, United Kingdom; Instituto de Maternidad y Ginecología Nuestra Señora de Las Mercedes, San Miguel de Tucumán, and iTrials-Hospital Militar Central and iTrials, Buenos Aires, Argentina; Clinical Research Prime, Idaho Falls, Idaho; Boeson Research, Missoula, Montana; Meridian Clinical Research, Hastings, Nebraska; Asian Hospital and Medical Center, Manila, the Philippines; Department of Pediatrics, Spaarne Gasthuis, Haarlem and Hoofddorp, the Department of Pediatrics, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, and the ReSViNET Foundation, Zeist, the Netherlands; Meilahti Vaccine Research Center MeVac, Inflammation Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; National Taiwan University Hospital, Taipei, Taiwan; the Department of Obstetrics and Gynecology, Sendai City Hospital, Sendai, Japan; Institute of Biomedical Sciences, University of Chile School of Medicine, Santiago, Chile; University of Otago and New Zealand Clinical Research, Christchurch, New Zealand; CHU Sainte-Justine, Montreal, Quebec, Canada; Hospital Moinhos de Vento and Pontifícia Universidade Católica RGS, Porto Alegre, Brazil; the Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; Arké SMO S.A. de C.V., Mexico City, Mexico; University of Western Australia School of Medicine, Vaccine Trials Group, Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, and Perth Children's Hospital, Nedlands, Western Australia, and Vaccine Clinical Research, Pfizer Inc, Sydney, Australia; and Worldwide Safety, Pfizer Srl, Milan, Italy.
Objective: To evaluate descriptive efficacy data, exploratory immunogenicity data, and safety follow-up through study completion from the global, phase 3 MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal vaccination trial of bivalent respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVpreF).
Methods: MATISSE was a phase 3, randomized, double-blinded, placebo-controlled trial. Healthy pregnant participants aged 49 years or younger at 24-36 weeks of gestation were randomized (1:1) to receive a single RSVpreF 120 micrograms or placebo dose.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!